|
Indian Pediatr 2014;51: 785-803 |
|
Indian Academy of Pediatrics (IAP) Recommended
Immunization Schedule for Children Aged 0 through 18 years –
India, 2014 and Updates on Immunization
|
Vipin M Vashishtha, Panna Choudhury, Ajay Kalra,
Anuradha Bose, Naveen Thacker,
Vijay N Yewale, CP Bansal and Pravin J Mehta
Indian Academy of Pediatrics, Advisory Committee on
Vaccines and Immunization Practices (ACVIP)
Correspondence to: Dr Vipin M Vashishtha, Convener,
IAP Advisory Committee on Vaccines and Immunization Practices, Mangla
Hospital and Research Center, Shakti Chowk, Bijnor, Uttar Pradesh 246
701, India.
Email: [email protected]
|
Justification: There is a need to review/revise recommendations
about existing vaccines in light of recent developments in the field
of vaccinology.
Process: Following an IAP
ACVIP meeting on April 19 and 20, 2014, a draft of revised
recommendations for the year 2014 and updates on certain vaccine
formulations was prepared and circulated among the meeting
participants to arrive at a consensus.
Objectives: To review and
revise recommendations for 2014 Immunization timetable for
pediatricians in office practice and issue statements on certain new
and existing vaccine formulations.
Recommendations: The major
changes in the 2014 Immunization Timetable include two doses of MMR
vaccine at 9 and 15 months of age, single dose recommendation for
administration of live attenuated H2 strain hepatitis A vaccine,
inclusion of two new situations in ‘high-risk category of children’
in context with ‘pre-exposure prophylaxis’ of rabies, creation of a
new slot at 9-12 months of age for typhoid conjugate vaccine for
primary immunization, and recommendation of two doses of human
papilloma virus vaccines with a minimum interval of 6 months between
doses for primary schedule of adolescent/preadolescent girls aged
9-14 years. There would not be any change to the committee’s last
year’s (2013) recommendations on pertussis vaccination and
administration schedule of monovalent human rotavirus vaccine. There
is no need of providing additional doses of whole-cell pertussis
vaccine to children who have earlier completed their primary
schedule with acellular pertussis vaccine-containing products. A
brief update on the new Indian Rotavirus vaccine, 116E is also
provided. The committee has reviewed and offered its recommendations
on the currently available pentavalent vaccine (DTwP+Hib+Hepatitis-B)
combinations in Indian market. The comments and footnotes for
several vaccines are also updated and revised.
Keywords: Immunity, Child, Guidelines, MMR
Vaccine, Vaccination.
|
The IAP Advisory Committee on Vaccines and
Immunization Practices (ACVIP) has recently reviewed and revised the
recommended immunization schedule for children aged 0 through 18 years
to ensure that the schedule reflects recommendations based on recent
evidences for licensed vaccines in the country. The first annual meeting
of the IAP ACVIP was held on 19th and 20th April 2014 in New Delhi. IAP
ACVIP members and invited experts who attended the meeting are listed in
Annexure 1. The aim of the meeting was to discuss and
debate recent developments in the field, to revise recommendations for
the IAP Immunization Timetable for the year 2014, and to issue
recommendations for available licensed vaccines in the country.
Following the meeting, a draft of revised immunization schedule for the
year 2014 was prepared and circulated among the meeting participants to
arrive at a consensus.
The detailed process behind issuing IAP
recommen-dations on immunization – primarily for the pediatricians in
office practice has been described earlier [1]. These recommendations
provide guidelines to a pediatrician on how best to utilize available
licensed vaccines in their office-practice settings. The members may use
their own discretion while using them in a given situation within the
framework suggested [2]. The existing National immunization schedule and
government policies are also taken into account while drafting
recommendations.
Aims and Objectives
To revise IAP Immunization Timetable for the year
2014, and review and issue recommendations on the available licensed
vaccines.
Recommendations for IAP Immunization Timetable, 2014
The IAP ACVIP has issued recommendations for the IAP
Immunization Timetable (Table I and
Fig. 1)
for the year 2014 that includes the following major changes from last
year:
TABLE I IAP Immunization Timetable 2014
I. IAP recommended vaccines for routine use
Age (completed wks/mo/y) |
Vaccines
|
Comments
|
Birth |
BCG |
Administer these vaccines to all newborns before hospital
discharge |
|
OPV 0 |
|
|
Hep-B 1 |
|
6 weeks |
DTwP 1 |
DTP: |
|
IPV 1 |
• DTaP vaccine/combinations should preferably be avoided for the
primary series |
|
Hep-B 2
Hib 1 |
• DTaP vaccine/combinations should be preferred in certain
specific circumstances/conditions only |
|
Rotavirus 1 |
|
|
PCV 1 |
• No need of repeating/giving additional doses of whole-cell
pertussis (wP) vaccine to a child who has earlier completed
their primary schedule with acellular pertussis (aP)
vaccine-containing products |
|
|
Polio: |
|
|
• All doses of IPV may be replaced with OPV if administration of
the former is not feasible |
|
|
• Additional doses of OPV on all supplementary immunization
activities (SIAs) |
|
|
• Two doses of IPV instead of 3 for primary series if started at
8 weeks, and 8 weeks interval between the doses |
|
|
• No child should leave the facility without polio immunization
(IPV or OPV), if indicated by the schedule |
|
|
Rotavirus:
|
|
|
• 2 doses of RV1 and 3 doses of RV5 |
|
|
• RV1 should be employed in 10 and 14 week schedule, instead of
6 and 10 week |
|
|
• 10 and 14 week schedule of RV1 is found to be far more
immunogenic than existing 6 and 10 week schedule |
10 weeks |
DTwP 2 |
Rotavirus:
|
|
IPV 2 |
• If RV1 is chosen, the first dose should be given at 10 weeks |
|
Hib 2 |
|
|
Rotavirus 2 |
|
|
PCV 2 |
|
14 weeks |
DTwP 3 |
Rotavirus: |
|
IPV 3 |
• Only 2 doses of RV1 are recommended at present |
|
Hib 3 |
• If RV1 is chosen, the 2nd dose should be given at 14 weeks |
|
Rotavirus 3 |
|
|
PCV 3 |
|
6 months |
OPV 1 |
Hepatitis-B: |
|
Hep-B 3 |
• The final (third or fourth) dose in the HepB vaccine series
should be administered no earlier than age 24 weeks and at least
16 weeks after the first dose |
9 months |
OPV 2
|
MMR: |
|
MMR-1 |
• Measles-containing vaccine ideally should not be administered
before completing 270 days or 9 months of life |
|
|
• The 2nd dose must follow in 2nd year of life |
|
|
• No need to give stand-alone measles vaccine |
|
|
Typhoid: |
9-12 months
|
Typhoid Conjugate Vaccine
|
• Currently, two typhoid conjugate vaccines, Typbar-TCV and
PedaTyph available in Indian market
|
|
|
• PedaTyph is not yet approved; the recommendation is
applicable to Typbar-TCV only |
|
|
• An interval of at least 4 weeks with the MMR vaccine should be
maintained while administering this vaccine |
|
|
• Should follow a booster at 2 years of age |
12 months |
Hep-A 1 |
Hepatitis A:
|
|
|
• Single dose for live attenuated H2-strain Hep-A vaccine
|
|
|
• Two doses for all killed Hep-A vaccines are recommended now |
15 months |
MMR 2 |
MMR: |
|
Varicella 1 |
• The 2nd dose must follow in 2nd year of life |
|
PCV booster |
• However, it can be given at anytime 4-8 weeks after the 1st
dose during 2nd year |
16 to 18 months
|
DTwP B1/DTaP B1 |
Varicella:
|
|
IPV B1, Hib B1 |
• The risk of breakthrough varicella is lower if given 15 months
onwards |
|
|
• The first booster (4th dose) may be administered as early as
age 12 months, provided at least 6 months have elapsed since the
third dose. |
|
|
DTP: |
|
|
• First and second boosters should preferably be of DTwP |
|
|
• Considering a higher reactogenicity of DTwP, DTaP can be
considered for the boosters |
18 months |
Hep-A 2 |
• 2nd dose for killed vaccines; only single dose for live
attenuated H2- strain vaccine
|
2 years |
Typhoid booster |
• Either Typbar-TCV® or Vi-polysaccharide (Vi-PS) can be
employed as booster; |
|
|
• Typhoid revaccination every 3 years, if Vi-polysaccharide
vaccine is used |
|
|
• Need of revaccination following a booster of Typbar-TCV® not
yet determined |
4 to 6 years
|
DTwP B2/DTaP B2 |
Varicella:
|
|
OPV 3 Varicella 2 |
• 2nd dose can be given at anytime 3 months after the 1st dose
|
|
Typhoid booster |
|
10 to 12 years |
Tdap/Td |
Tdap:
|
|
HPV
|
• Tdap is preferred to Td followed by Td every 10 years |
|
|
HPV:
|
|
|
• Only 2 doses of either of the two HPV vaccines for
adolescent/pre-adolescent girls aged 9-14 years |
|
|
• For girls 15 years and older, and immunocompromised
individuals 3 doses are recommended |
|
|
• For two-dose schedule, the minimum interval between doses
should be 6 months. |
|
|
• For 3 dose schedule, the doses can be administered at 0, 1-2
(depending on brands) and 6 months
|
II. IAP recommended vaccines for High-risk* children
(Vaccines under special circumstances) |
1-Influenza Vaccine
|
2-Meningococcal Vaccine
|
3-Japanese Encephalitis Vaccine
|
4-Cholera Vaccine
|
5-Rabies Vaccine
|
6-Yellow Fever Vaccine
|
7-Pneumococcal Polysaccharide vaccine (PPSV 23)
|
* High-risk category of children: Congenital
or acquired immunodeficiency (including HIV infection); Chronic
cardiac, pulmonary (including asthma if treated with prolonged
high-dose oral corticosteroids), hematologic, renal (including
nephrotic syndrome) and liver disease; Children on long term
steroids, salicylates, immunosuppressive or radiation therapy;
Diabetes mellitus, Cerebrospinal fluid leak, Cochlear implant,
Malignancies; Children with functional/ anatomic asplenia/
hyposplenia; During disease outbreaks; Laboratory personnel and
healthcare workers; Travelers; Children having pets in home;
Children perceived with higher threat of being bitten by dogs
such as hostellers, risk of stray dog menace while going
outdoor. |
A. Measles and MMR vaccination
Recommendation: The committee has revised its
recommendations on Measles and MMR vaccination schedule. The new
schedule will have a dose of MMR at 9 months instead of measles, and
another dose (2nd) at 15 months of age. The earlier recommendation of
2nd dose of MMR at 4-6 years of age has been removed.
The need and justification: NTAGI Standing
Technical Sub-Committee (STSC) recommended two doses of Measles –
Rubella (MR) vaccines in the Universal immunization program (UIP) at 9
months and 16-24 months at the time of 1st booster of DTP vaccine. Since
the Academy has argued very strongly in favor of MMR instead of MR
vaccine in UIP schedule, the revised recommendations will facilitate
inclusion of Mumps vaccine in the National immunization program in near
future. Furthermore, it will be more in sync with the upcoming UIP
schedule. The detailed reasons are discussed in another recent position
paper from IAP publication [3].
The evidence: There are many studies both
from India and from other countries demonstrating efficacy and safety of
MMR vaccine given at 9 month of age [3-8].
B. Live attenuated Hepatitis A vaccine
Recommendation: The committee has revised its
recommendations on administration schedule of live attenuated hepatitis
A vaccine, based on the viral H2 strain (Chinese vaccine). Now a single
dose of this vaccine is recommended at 12 months of age over-riding the
previous recommendation [9] of two doses of the same vaccine.
The justification and evidence: The
committee reviewed both published [11,12] and unpublished long term
follow-up data on immunogenicity and safety of a single dose of this
vaccine from trials in India. The data showed 79.3% of 121 children were
seroprotected (anti-HAV titers >20 mIU/mL) up to 6 years follow-up in
the pivotal single center study, whereas 97.3% of 111 children had shown
seroprotection after 5 years of follow-up period in the multi-centric
group. In the multi-centric study [12], the test subjects maintained
good GMT levels even after 5 years of follow-up. The committee had
earlier shown its concern on waning of seroprotection in a subgroup of
individuals of original single-center study cohort [2]. However, it was
later disclosed that only ten subjects had shown this phenomenon, and
most of these subjects were of comparatively higher age groups than
other study subjects. The decision was also facilitated by the SAGE/WHO
recommendations of single dose of live attenuated hepatitis A vaccine
[10].
C. Rotavirus Vaccines
Monovalent rotavirus vaccine, RV1
The committee reviewed new data on administration
schedule of RV1 (Rotarix) from Pakistan [13] and Ghana [14]. In both
studies, the seroconversion and GMTs were higher at delayed (10 and 14
weeks) than early (6 and 10 weeks) schedule, though not statistically
significant [13, 14]. In Ghana study, the seroconversion and GMTs were
significantly higher in 3-dose (6, 10 and 14 week) schedule than 2-dose
early (6 and 10 week) schedule [14]. As these studies are yet
unpublished, full methodology and results are not available for
scrutiny. The available results do not warrant any change in the
existing schedule of RV1 vaccine that includes the first dose at 10
weeks of age instead of 6 weeks in order to achieve better immune
response, and the second dose at 14 weeks to fit with existing National
immunization schedule [9].
Indian rotavirus vaccine, 116 E
This vaccine developed by Bharat Biotech (Rotavac) is
a live, naturally attenuated vaccine containing monovalent, bovine human
reassortant strain characterized as G9 P [11], with the VP4 of bovine
rotavirus origin, and all other segments of human rotavirus origin. The
vaccine strain was isolated from asymptomatic infants with mild diarrhea
by Indian researchers in 1985 at AIIMS, New Delhi. Follow up of these
infants indicated that they were protected against severe rotavirus
diarrhea for up to 2 years. This strain was sent for vaccine development
to the National Institute of Health by Department of Biotechnology,
India, and later transferred to Bharat Biotech International Limited in
2001 for further development.
In a phase II study, both low (10 4
ffu) and high (105 ffu)
dosages of 116E were found safe in infants between 8 and 20 weeks of
age. IgA immunogenicity rates for the 105
ffu dosage were 64.7% after 1 dose, and 89.7% after 3 doses. The vaccine
virus was shed in about 20% of infants [15].
A randomized, double-blind, placebo-controlled phase
III clinical trial [16] amongst 6,799 infants was conducted at three
sites in India. The first year efficacy against severe rotavirus
diarrhea was 53·6% (95% CI 35·0-66·9; P=0·001) with protection
continuing into the second year of life also. The vaccine also showed
20% efficacy against all-cause severe diarrhea admission. Six cases of
intussusceptions (all occurring after administration of 3rd dose) were
recorded in the vaccinees and two in the control group. This vaccine has
already been licensed in India and would soon be available for use in
Indian market.
The committee reviewed the evidence and opined it to
be a moderately effective vaccine against rotavirus diarrhea in India.
As this is the only vaccine that has undergone large scale field-
efficacy trial in India, the level of evidence regarding its efficacy is
rated higher by the committee. However, the committee stresses the need
of having large scale studies, particularly post-marketing surveillance
to monitor occurrence of acute intussusception amongst vaccinated
children. There seems to be one excess case of intussusception for every
2000 children vaccinated. Apparently, the sample size was not adequately
powered to look for statistical significance [16]. Regarding use of the
vaccine in office-practice, it is not clear whether pediatricians would
be able to use it in coming months since information about formulation
and commercial availability of the vaccine is not yet available.
D. Pre-exposure prophylaxis for rabies
Recommendations for office practice: The
committee has now recommended that practically all children need
vaccination against rabies and following two situations to be included
in high-risk category of children for rabies vaccination: (i)
children having pets at home; and (ii) children perceived with
higher threat of being bitten by dogs such as hostellers, and those with
risk of stray dog bite while going outdoor. These children should be
offered pre-exposure prophylaxis (Pre-EP) against rabies. This must be
preceded by a one-to-one discussion with the parents. The Pre-EP is not
included in the IAP immunization schedule for all children. Three doses
are recommended to be given intramuscularly on days 0, 7 and 28 (day 21
may be used if time is limited, as with imminent travel, but day 28 is
preferred). The intradermal schedule has been shown to be effective, but
is not approved for this purpose in office practice.
There are studies to show that good antibody levels
persist up to 10 years even after a 3 dose pre-exposure prophylaxis
followed by a booster at one year. However, on account of the nature of
the disease, for re-exposure at any point of time after completed and
documented, pre-or post-exposure prophylaxis, two doses are to be given
on days 0 and 3. Rabies immunoglobulins (RIG) are not needed in these
children. There is no change in the IAP recommendations for
post-exposure prophylaxis (PEP) of rabies.
Public use: The committee urges the
Government of India (GoI) to urgently take remedial measures to address
the huge burden of rabies in India [17]. These measures include public
education campaigns, need to ensure the uninterrupted availability of
vaccines and anti-rabies immunoglobulin in primary health care
facilities and training of primary care providers (including
pediatricians), vaccination of dogs, sterilization of stray dogs, and
declaration of rabies as a notifiable disease. The committee reiterated
its position that universal Pre-EP vaccination, especially for children,
could reduce the number of human rabies dramatically. Use of intradermal
vaccination would bring down the vaccine cost for universal vaccination
program dramatically [2].
Justifications: The advantages of the
Pre-EP include elimination of the need for RIG, reduction in the number
of vaccine doses on exposure and provision of immunity to individuals
whose post-exposure prophylaxis is delayed. Further, the likelihood of
lack of documentation of a dog bite amongst young children who may not
report scratches and small playful bites from dogs and cats are other
reasons why Pre-EP would be useful. However, it was agreed upon that
inclusion of Pre-EP in only IAP schedule for office practice would not
serve the desired purpose since majority of deaths occur among children
belonging to low socioeconomic strata and those living in remote areas
[17]. WHO encourages the implementation of carefully designed studies on
the feasibility, cost-effectiveness and long-term impact of
incorporating ‘Cell Culture Vaccines and Embryonated egg-based vaccines’
(CCEEVs) into the immunization programs of infants and children where
canine rabies is a public health problem [18].
E. Typhoid conjugate vaccines
Recommendation for office practice
Primary schedule: The committee has now
created a new slot for typhoid conjugate vaccine for primary
immunization at 9-12 months of age in the IAP Immunization schedule.
There are currently two typhoid conjugate vaccines (Typbar-TCV and
PedaTyph), available and licensed in the country. However, this
recommendation would be applicable only to the former as the committee
is awaiting more data on the latter. Only a single dose of the vaccine
is recommended for primary series. An interval of at least 4 weeks with
the measles/MMR vaccine should be maintained since the data on
interference with the measles/MMR vaccine are not yet available.
Boosters: Those who received a dose of
conjugate vaccine at 9-12 months can be prescribed booster of either
Vi-polysaccharide (Vi-PS) or the conjugate vaccine at 2 years of age.
Those who have received booster of Vi-PS vaccine will need revaccination
every 3 years till the intended duration of protection. There is no
evidence of hypo-responsiveness on repeated vaccination so far. The need
of further boosters after conjugate vaccine is not yet determined since
long term data are not yet available.
Catch-up schedule: Catch-up vaccination is
recommended throughout the adolescent period, i.e. up to 18 years of
age. Below 2 years, only conjugate vaccine is recommended while above 2
years of age any of the two can be employed. The details about further
schedule should be followed as described above in the ‘boosters’
section.
Recommendations for public use
The committee strongly urges the GoI to include
universal typhoid vaccination in its UIP all over the country at the
earliest.
Evidence and justification: The committee
believes that considering the epidemiology of typhoid in the country,
there is definite need of protection against typhoid fever below 2 years
of age. The Vi-PS vaccines are ineffective below 2 years of age and
provide modest and short lasting protection. There is definite need of
typhoid conjugate vaccines, effective below 2 years of age and capable
of providing superior long-lasting protection. The committee reviewed
the published [19] and unpublished data of new typhoid conjugate
vaccines, (BBIL’s Typbar-TCV, BioMed’s PedaTyph and Novartis’s
Vi-CRM197). All these vaccines can be administered at and around 9
months of age. Only a single dose is sufficient for adequate
seroconversion for primary immunization, and the second dose failed to
show incremental effect on antibody titers (data after 2nd dose of
PedaTyph are not yet available). In the published trial of Novartis’s
Vi-CRM197 conjugate typhoid vaccine [19], a low response was noted to
measles, hepatitis B and H influenza type b both in reference (PCV13)
and test vaccine (conjugate typhoid vaccine) groups, with a
non-significant reduction in the rate of measles seroconversion in the
test vaccine group in one center. The committee has thus recommended
maintaining an interval of at least 4 weeks with the measles/MMR vaccine
while administering this vaccine. The committee has also asked the
manufacturer to undertake a ‘measles/MMR interference study’ with
vaccination at 9 months.
Regarding the need and timing of boosters, the data
provided by the manufacturer of Typbar-TCV vaccine show almost 100%
seroprotection (>7.2 EU/mL) of test vaccine in both the cohorts (6 mo-2
years and 2-45 years) till 18 months of follow-up, although both
seroconversion (>4-fold rise of antibody level) and GMT levels waned
significantly in both cohorts. Regarding comparison of Vi-PS
non-conjugate vaccine with the Vi-PS conjugate vaccine, both fared
equally well above 2 years of age as far as immediate and long-term
seroconversion are concerned, although the latter had significantly
higher GMTs and slightly better seroconversion rates than the former.
The committee has thus recommended either of the vaccines as a booster
at 2 years of age. The need of repeat doses/boosters for conjugate
vaccine shall only be determined after long-term efficacy data are
available.
F. Human Papillomavirus (HPV) vaccination schedule
Recommendations: Two doses of HPV vaccine are
advised for adolescent/pre-adolescent girls aged 9-14 years; for girls
15 years and older, current 3 dose schedule will continue. For two-dose
schedule, the minimum interval between doses should be 6 months. The
interval between the first and second dose may be extended upto12
months, should this facilitate administration – say in school settings.
For girls, primed before the age of 15 years, even if older at the time
of second dose, a two-dose schedule will be applicable. However, for
immuno-compromised individuals, including HIV-infected, the three-dose
schedule is recommended, irrespective of age.
Evidence and justification: IAP had
recommended use of HPV vaccine in its immunization schedule way back in
2007. Though there is no coverage data on uptake of this vaccine through
private sector, the common perception is that acceptance is poor and the
coverage still remains miniscule. The move to revise HPV vaccine
immunization schedule for adolescent girls from existing three to two
doses would not only be cost-saving, but would also simplify logistics
like increased flexibility of the intervals, and annual doses for
school-based delivery. Hence, the revised recommendations may help in
improving acceptance, facilitating delivery, and enhancing coverage of
the vaccine.
The WHO’s Strategic Advisory Group of Experts (SAGE)
working group (WG) on HPV has recommended revision of vaccination
schedule for pre-adolescent and adolescent girls from three primary
doses to two in its April 2014 meeting [20]. The committee has reviewed
the background material and various trials conducted in this regard so
far [21]. The main source of evidence is provided by a systematic review
commissioned by SAGE WG [22]. The other sources include review of the
data from observational studies on 2 versus 3 dose schedule, and
proceedings of an Ad hoc Expert Consultation on HPV vaccine schedules
organized in Geneva, 2013 [21]. The European Medicines Agency (EMA) has
also approved two doses for pre-adolescent and adolescent girls aged
9-14 years for the bivalent HPV vaccine and also offered positive
opinion for a similar schedule for quadrivalent vaccine [23]. Many
countries have either already adopted or are planning to adopt a
two-dose schedule [21]. Few countries like Brazil, Mexico, Columbia and
British Columbia are running an extended schedule (2+1, i.e. 0,
6, 60 months) where the last dose at 5 years depends on follow-up
assessment of the need [21]. In Costa Rica, strong 4 year protection was
reported in women who received just one dose of bivalent HPV vaccine
[21].
The systematic review [22] has identified various
studies that include both randomized and non-randomized trials of both
the vaccines, bivalent and quadrivalent, from various high income group
countries like Canada, Australia, Sweden, Denmark, Germany, and low and
middle income (LMI) countries like Uganda, Mexico, and India. In
randomized comparisons of two-dose and three-dose schedules (overall 3
RCTs), seroconversion and seropositivity were non-inferior or
inconclusive at all-time points. In non-randomized comparisons, all
available data for seroconversion and seropositivity showed
non-inferiority of the 2-dose compared with the 3-dose schedule. The
efficacy against virological endpoints in initially HPV-naïve subjects
who received 2 doses of bivalent vaccine at 48th month indicates that
the two-dose schedule prevents HPV-16/18 infection in subjects who did
not receive a complete 3-dose vaccination course. The review also
compared different intervals between doses of HPV vaccine. The 6-month
interval resulted in superior GMCs compared with the 2-month interval
one month after the last vaccine dose in all the age groups enrolled.
The mathematical models also support the two-dose
schedule for girls aged 9-14 years. In one such model it was shown that
in high-income settings (such as the UK and Canada), if it was
documented that a 2-dose vaccination conferred more than 10-20 years
protection then adding the third dose would not be cost-effective [21].
The cost-effectiveness of 2-dose vs. 3-dose vaccination in
low/middle income settings still needs to be explored.
The committee’s recommendations are also facilitated
by the evidence generated by an ongoing multi-centric RCT on alternative
dosing schedule of quadrivalent HPV vaccine in India [24-26]. In this
trial, comparisons favored the 2-dose schedule and the ratio of antibody
levels was higher in the 2-dose group than in 3-dose group [25,26]. The
GMCs for HPV18 in the 2-dose group were non-inferior to that in the
3-dose group. However, on clinical outcomes basis, the RCT provided only
limited data, and incident infections with any of the vaccine types in
the quadrivalent vaccine were more common in the 2-dose than in the
3-dose group [25,26].
The magnitude of the vaccine response is determined
by the age at the first dose. The review of different trials have shown
that 100% adolescents can be primed with a single dose of the vaccine
and the second dose after 6 months results in higher (almost twice) peak
titers in adolescents than in adults. These antibodies then plateau for
about 12 months after the peak and decline very slowly providing a long
lasting protection [21]. There are limited data from HIV-infected
individuals receiving a 3-dose schedule and no data from HIV-infected
individuals receiving a 2-dose schedule.
The committee concludes that two doses of HPV vaccine
in girls 9-14 years of age are non-inferior in terms of immunogenicity
when compared to three doses in girls 9-14 years or 15-24 years of age.
A 2-dose vaccine schedule is likely to be as efficacious as three doses,
even though long-term outcome and clinical efficacy data are not yet
available. The committee stresses the need of long-term studies on
efficacy/effectiveness of alternative schedules.
G. Update on Pertussis immunization
Recommendation: In lieu with its earlier
recommendations on pertussis vaccination [9], the committee clarifies
that there is no need of repeating or giving additional doses of
whole-cell pertussis (wP) vaccine in order to boost immunity in children
who have earlier completed their primary schedule with acellular
pertussis (aP) vaccine-containing products. However, it should be
ensured that all the remaining doses are wP vaccine-containing products.
This is to be reiterated here that wP vaccine is permitted till 7 years
of age.
Justification: Although it is reported that
presence of even a single dose of wP vaccine in the primary infant
series of pertussis immunization was found to be providing superior
priming and more durable immunity than the schedule completed with only
aP containing vaccines [9,27], nevertheless, the aP vaccines are also
effective and do offer protection against the disease. Since no
stand-alone preparation of wP vaccine is available in the market, it is
not advisable to administer too many doses of pertussis-containing combo
products (that usually also contain diphtheria and tetanus toxoids) that
may inadvertently enhance the frequencies of undesirable adverse events
associated with their use.
H. Pentavalent (DTwP+Hib+Hepatitis-B) vaccine
There are concerns amongst pediatricians related to
the quality, suitability and preference of available different wP-vaccine
containing pentavalent vaccines in the market since the publication of
IAP recommendations on pertussis immunization [9]. Intensive marketing
strategies of vaccine manufacturers have further aggravated this
confusion. There are no data on either efficacy/effectiveness of
individual wP product or comparative evaluation of different available
wP combinations in Indian market. ACVIP has urged the National
Regulatory Authority (NRA) to setup indigenous National guidelines to
manufacture and market different pertussis vaccines in the country [27].
In this background, the committee reviewed the evidence related to
available wP-based pentavalent combinations in the country. There are
currently six different brands available in Indian market (Table
II). All pentavalent vaccines, except Quinvaxem-TM contain PRP-T
as carrier protein conjugated with Hib PRP antigen whereas CRM-197 is
used in the latter. Both these carrier proteins are consistently highly
immunogenic after completion of three primary doses in infants [28-31].
Similarly, no statistically significant difference was found in the
safety profile of Hib vaccines containing these two carrier proteins
after completion of three doses [28]. Regarding the adjuvant, all the
pentavalent products contain Aluminium phosphate in a WHO-prescribed
quantity (<1.25 mg) [32]. All the pentavalent combinations, except
Quinvaxem, contain thiomersal as preservative. Even the latter also has
traces of thiomersal as residue. The committee supports the WHO policy
on this issue which continues to recommend the use of thiomersal in
vaccines used for global immunization programs since the benefits of
using such products far outweigh any theoretical risk of toxicity
[32,33].
All the brands are approved by Indian National
Regulatory Authority (NRA), Central Drugs Standard Control Organization
(CDSCO), MoHFW, GoI after reviewing their phase III clinical
immunogenicity and safety studies. However, only the trials of Pentavac,
Shan5 and Quinvaxem are published in peer-reviewed journals and
available in public domain [34-36]. Information about other brands (Easyfive-TT,
Comvac-5, and ComBEfive) are obtained through clinical trial data
submitted to CDSCO and package inserts [37-40].
Efficacy: Though direct comparisons are not
possible – due to differences in data collection, assays used for
evaluation of the immune response, and analysis methods – the
seroconversion rates for all the five antigens except for pertussis
antigen (which were found lower for Comvac5 and Easyfive-TT) were
comparable for all the six brands (Table II). However, the
seroconversion rates of Comvac5 and Easyfive-TT against pertussis were
comparable to the comparator vaccines’ arms. It has to be noted that
till date no known single correlate of protection for pertussis exists,
nor any established protective antibody levels are known. Antibody
responses to pertussis antigens are variable amongst wP vaccines, likely
related to the variability of antigen content amongst them. Furthermore,
many different assays are used by manufacturers for the assessment of
the immunogenicity.
Reactogenicity: Regarding reactogenicity profile
of available brands, a marked diversity was noted. Pentavac was found to
be the most reactogenic while Quinvaxem the least. However, it is to be
noted that no comparator vaccine was used in Indian trial of Quinvaxem
[36] and the reactogenicity profile of the former was found comparable
or even superior to the CRM197-based comparator (Easyfive) vaccine (34).
Similarly, in the case of Easyfive-TT, the test vaccine fared equally
well to the comparator vaccine (Tritanrix+Hiberix) as far as
reactogenicity profile is concerned [38,39]. Further, they did not
provide information regarding the number of subjects having fever >38ºC.
There is no study where all these products are compared ‘head-to-head’
with each other at the same time. On the other hand when one product was
compared with another, they fared comparably well against each other.
Hence, the committee concludes that all the available pentavalent
products are comparable as far as immunogenicity and reactogenicity
profile are concerned.
There is no efficacy, effectiveness or post-marketing
surveillance (PMS) study from India available in public domain for any
of these pentavalent products. There is a large PMS adverse event
surveillance study of around 3000 children from Guatemala for Quinvaxem
[41].
WHO pre-qualification and world-wide usage: All
the products except Comvac-5 are now WHO prequalified [42]. While the
Quinvaxem (since 2006), Pentavac (since 2010), and ComBEfive (since
2012) have never been delisted since attaining pre-qualification, the
Easyfive-TT (2011-12) and Shan5 (2010-2013) had to be delisted after
attaining this status for variety of reasons. Quinvaxem is the most
widely used pentavalent vaccine with >400 million doses used globally
[43].
The wP vaccines are standardized by protection in the
‘mouse cerebral test’, not by specific antigen content. The committee
acknowledges the fact that the process for standardization of quality
and efficacy of pertussis vaccines is challenging. Since randomized
controlled studies of protective efficacy are no more permitted now
owing to ethical and logistic reasons, the post-marketing surveillance
and population-based ‘vaccine effectiveness studies’ assume great
significance. WHO has made it mandatory to conduct periodic
post-marketing surveillance of any newly launched wP based product to
monitor its safety since limited safety data are obtained in
pre-licensure studies [32].
WHO pre-qualification guidelines for a new wP
vaccine, or a new formulation, require proof of concept in a relevant
animal model in terms of both potency and safety. The NRAs are guided to
ensure potency and safety of a new wP vaccine in preclinical evaluation
through ‘intracerebral mouse protection test’ and ‘mouse weight gain
test’ before granting clinical testing of a new wP vaccine containing
product [32]. Regarding clinical evaluation, determination of antibody
response to individual, specific antigens (at least one assay used
should determine antibodies against pertussis toxin) is recommended
rather than the measurement of antibodies against whole cell or whole
cell extracts. The WHO uses very stringent protocol for awarding
pre-qualification status to a wP vaccine product [44]. They issue
guidelines to NRAs to ensure their application while licensing a wP-
based combination in a country. Hence, achieving WHO pre-qualification
assumes a very high significance as far as potency, efficacy and safety
of any wP based product is concerned. The ACVIP also acknowledges that
achieving WHO pre-qualification, which is a dynamic ongoing process with
periodic assessment, is a must for all these products to achieve the
committee’s approval.
Cost: All the currently available liquid
pentavalent combinations cost around INR 600, except Quinvaxem which is
around 2.5 times more expensive (Table II). The committee
thinks the price of the product cannot be justified considering all the
attributes and performance.
Major Changes in Recommendations for IAP Immunization
Timetable, 2014
Measles and MMR immunization
• Two doses of MMR at 9 and 15 months
• No stand alone measles dose at 9 months
• No MMR at 4-6 years of age
Typhoid immunization
• Slot for ‘typhoid conjugate vaccine’ for primary immunization
at 9-12 months of age
• Recommendation applicable only for Typbar-TCV
• Booster of either Typbar-TCV or Vi-polysaccharide (Vi-PS)
vaccine at 2 years of age
• Typhoid revaccination every 3 years, if Vi-polysaccharide
vaccine is used
• Need of revaccination following a booster of Typbar-TCV not
yet determined
Hepatitis-A immunization
• Single dose administration of live attenuated H2 strain
hepatitis A vaccine at 12 months
• Previous recommendations of two-dose is now scrapped
• Two doses for inactivated (killed) Hepatitis-A vaccine
Human Papillomavirus (HPV) vaccination
• Two doses of HPV vaccine for adolescent/preadolescent girls
aged 9-14 years
• For two-dose schedule, the minimum interval between doses
should be 6 months
• Three dose schedule for adolescent girls aged 15 years and
older to continue
Rabies immunization
• Two new situations, children having pets in home and
children perceived with higher threat of being bitten by dogs to
be included in ‘high-risk category of children’ for rabies
vaccination
• These groups of children should now be offered ‘pre-exposure
prophylaxis’ against rabies
Pertussis immunization
• No change in pertussis immunization recommendations of 2013
• No need of repeating/giving additional doses of wP vaccine to
children who had earlier completed their primary schedule with
aP vaccine-containing products
• Review and recommendations on the currently available wP
vaccine containing pentavalent (DTwP+Hib+ Hepatitis-B) products
in Indian market
Other changes
• A brief update and recommendation on use of new Indian
Rotavirus vaccine, 116E
• The comments and footnotes for several vaccines are also
updated and revised |
Conclusions: The ACVIP concludes that all
the available liquid pentavalent combinations satisfy the licensing
criteria set by the Indian NRA and fulfills the requirement of WHO
prequalification, except Comvac-5. There is nothing to choose between
these products as far as their composition, efficacy and reactogenicity
profiles are concerned. However, the lack of published studies on
immunogenicity and safety of Comvac-5 and Easyfive-TT, and
non-attainment of WHO pre-qualification by the former are indeed source
of concern to the committee. Although, Quinvaxem has got highest
experience as far as worldwide usage is concerned, the committee
believes the product is definitely overpriced. There is an urgent need
of conducting large scale PMS studies on the safety and effectiveness of
these products in India. The committee urges the CDSCO, MoHFW, GoI to
issue notices to the manufacturers to conduct, generate and submit data
through PMS studies on the safety and effectiveness of their products.
Funding: None; Competing interests:
None stated.
IAP Advisory Committee on Vaccines & Immunization
Practices, 2013-14: Office-bearers: CP Bansal (Chairperson),
Rohit Agarwal (Co-chairperson), Vijay Yewale (Co-chairperson), Vipin M
Vashishtha (Convener), Pravin J Mehta (lAP Coordinator), Members:
Shashi Vani, Anuradha Bose, Ajay Kalra, AK Patwari, Surjit Singh;
Consultants: Naveen Thacker, NK Arora, Rajesh Kumar, HPS Sachdev, VG
Ramchandran, Ajay Gambhir; Rapporteur: Panna Choudhury.
Special invitees: Maharaj Kishan Bhan
(Ex-secretary, DBT, GoI, New Delhi), Monjori Mitra, (Institute of Child
Health, Kolkata), Sangeeta Yadav (Maulana Azad Medical College, New
Delhi), Jyoti Joshi Jain (Immunization Technical Support Unit, MoH& FW,
Public Health Foundation of India)
References
1. Indian Academy of Pediatrics Committee on
Immunization (IAPCOI). Consensus recommendations on immunization and IAP
immunization timetable 2012. Indian Pediatr. 2012;49:549-64.
2. Vashishtha VM, Choudhury P, Bansal CP, Yewale VN,
Agarwal R. editors. IAP Guidebook on Immunization 2013-2014. National
Publication House, Indian Academy of Pediatrics, Gwalior, 2014.
3. Vashishtha VM, Yewale VN, Bansal CP, Mehta PJ. IAP
perspectives on measles and rubella elimination strategies. Indian
Pediatr. 2014;51:719-22.
4. Schoub BD, Johnson S, McAnerney JM, Wagstaff LA,
Matsie W, Reinach SG, et al. Measles, mumps, and rubella
immunization at nine months in a developing country. Pediatr Infect Dis
J. 1990;9:263-7.
5. Singh R, John TJ, Cherian T, Raghupathy P. Immune
response to measles, mumps and rubella vaccine at 9, 12 & 15 months of
age. Indian J Med Res. 1994; 100:155-9.
6. Forleo-Neto E, Carvalho ES, Fuentes IC, Precivale
MS, Forleo LH, Farhat CK. Seroconversion of a trivalent measles, mumps,
and rubella vaccine in children aged 9 and 15 months. Vaccine.
1997;15:1898-901.
7. Yadav S, Thukral R, Chakarvarti A. Comparative
evaluation of measles, mumps and rubella vaccine at 9 & 15 months of
age. Indian J Med Res. 2003;118:183-6.
8. Goh P, Lim FS, Han HH, Willems P. Safety and
immunogenicity of early vaccination with two doses of tetravalent
measles-mumps-rubella (MMRV) vaccine in healthy children from 9 months
of age. Infection. 2007;35:326-33.
9. Indian Academy of Pediatrics, Advisory Committee
on Vaccines and Immunization Practices (ACVIP), Vashishtha VM, Kalra A,
Bose A, Choudhury P, Yewale VN, et al. Indian Academy of
Pediatrics (IAP) recommended immunization schedule for children aged 0
through 18 years, India, 2013 and updates on immunization. Indian
Pediatr. 2013;50:1095-108.
10. Bhave S, Bavdekar A, Madan Z, Jha R, Bhure S,
Chaudhari J, et al. Evaluation of immunogenicity and tolerability
of a live attenuated hepatitis A vaccine in Indian children. Indian
Pediatr. 2006;43:983-7.
11. Faridi MM, Shah N, Ghosh TK, Sankaranarayanan VS,
Arankalle V, Aggarwal A, et al. Immunogenicity and safety of live
attenuated hepatitis A vaccine: A multicentric study. Indian Pediatr.
2009;46:29-34.
12. World Health Organization. WHO position paper on
hepatitis A vaccines – June 2012. Wkly Epidemiol Rec. 2012;87:261-76.
13. Ali SA, Kazi M, Cortese M, Fleming J, Parashar U,
Jiang B, et al. Impact of Different Dosing Schedules on the
Immunogenicity of the Human Rotavirus Vaccine in Children in Pakistan –
a Randomized Controlled Trial (Abstract). Proceedings of the Vaccine for
Enteric Disease. 2013 Nov 6-8; Bangkok, Thailand.
14. Armah G, Lewis K, Cortess M, Parashar U, Ansah A,
Gazley L, et al. Immunogenicity of the Human Rotavirus Vaccine
Given on Alternative Dosing Schedules in Rural Ghana. Proceedings of the
Vaccine for Enteric Disease. 2013 Nov 6-8; Bangkok, Thailand.
15. Bhandari N, Sharma P, Taneja S, Kumar T,
Rongsen-Chandola T, Appaiahgari MB, et al. A dose-escalation
safety and immunogenicity study of live attenuated oral rotavirus
vaccine 116E in infants: A randomized, double blind, placebo-controlled
trial. J Infect Dis. 2009;200: 421-9.
16. Bhandari N, Rongsen-Chandola T, Bavdekar A, John
J, Antony K, Taneja S, et al. Efficacy of a monovalent
human-bovine (116E) rotavirus vaccine in Indian infants: A randomised,
double-blind, placebo-controlled trial. Lancet. 2014 Mar 11 [E-pub ahead
of print].
17. Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao
NS, Ashwath Narayana DH, Abdul Rahman S, et al. Assessing the
burden of human rabies in India: results of a national multi-center
epidemiological survey. Int J Infect Dis. 2007; 11:29-35.
18. World Health organization. Rabies vaccines: WHO
position paper. Wkly Epidemiol Rec. 2010;85:309-20.
19. Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E,
Ariff S, Soofi SB, et al. Immunogenicity and safety of the
Vi-CRM197 conjugate vaccine against typhoid fever in adults, children,
and infants in south and southeast Asia: results from two randomized
observer-blind, age de-escalation, phase 2 trials. Lancet Infect Dis.
2014;14:119-29.
20. World Health Organization. Summary of the SAGE
April 2014 Meeting. Available from:
http://www.who.int/immunization/sage/meetings/2014/april/report_
summary_april_2014/en/. Accessed June 15, 2014.
21. World health Organization. Evidence Based
Recommendations on Human Papilloma Virus (HPV) Vaccines Schedules.
Background paper for SAGE discussions, March 11, 2014. Available from:
http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_
Appendices2_3.pdf?ua=1. Accessed June 15, 2014.
22. D’Addario M, Scott P, Redmond S, Lowet N. HPV
vaccines: Review of alternative Vaccination Schedules: Preliminary
Overview of the Literature. University of Bern, Bern, Switzerland.
Report to WHO 3rd March 2014 (unpublished).
23. European Medicines Agencies, Committee for
Medicinal Products for Human Use (CHMP), Assessment report-Cervarix,
EMA/789820/2013, 21 November 2013. Available from:
htpp://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Assessement
Report –Variation/human/000721/WC500160885.pdf. Accessed June 30,
2014.
24. Sankaranarayanan R. Two vs three doses HPV
vaccine schedule: low- and middle-income countries, in Eurogin 2013
International Multidisciplinary Congress. 2013: Florence, Italy.
25. Sankaranarayanan R. Trial of two versus three
doses of Human Papillomavirus (HPV) vaccine in India. 2013 [cited 2013
Nov 15]; Available from: http://clinicaltrials. gov/show/NCT00923702.
Accessed July 4, 2014.
26. Sankaranarayanan R, Evaluation of fewer than
three doses of HPV vaccination in India, in WHO Consultation Meeting.
2013: WHO, Geneva.
27. Vashishtha VM, Bansal CP, Gupta SG. Pertussis
vaccines: Position paper of Indian Academy of Pediatrics (IAP). Indian
Pediatr. 2013; 50:1001-9.
28. Decker MD, Edwards KM, Bradley R, Palmer P.
Comparative trial in infants of four conjugate Haemophilus influenzae
type b vaccines. J Pediatr. 1992; 120:184-9.
29. Knuf M, Kowalzik F, Kieninger D. Comparative
effects of carrier proteins on vaccine-induced immune response. Vaccine.
2011; 29:4881-90.
30. Granoff DM, Anderson EL, Osterholm MT, Holmes SJ,
McHugh JE, Belshe RB, et al. Differences in the immunogenicity of
three Haemophilus influenzae type b conjugate vaccines in
infants. J Pediatr. 1992;121:187-94.
31. American Academy of Pediatrics Committee on
Infectious Diseases: Haemophilus influenzae type b conjugate
vaccines: Recommendations for immunization with recently and previously
licensed vaccines. Pediatrics. 1993; 92:480-8.
32. World Health Organization, WHO Technical Report
Series No 941, 2007. Annex 6 Recommendations for whole-cell pertussis
vaccine. Available from:
http://www.who.int/biologicals/publications/trs/areas/vaccines/whole_cell_
pertussis/Annex%206%20whole%20cell%20pertussis. pdf. Accessed July
7, 2014.
33. World Health Organization. Vaccines and
biologicals: Recommendations from the Strategic Advisory Group of
Experts. Wkly Epidemiol Rec. 2002; 37:306.
34. Sharma H, Yadav S, Lalwani S, Gupta V, Kapre S,
Jadhav S, et al. A phase III randomized, controlled study to
assess the immunogenicity and tolerability of DTPw-HBV-Hib, a liquid
pentavalent vaccine in Indian infants. Vaccine. 2011; 29:2359-64.
35. Rao R, Dhingra MS, Bavdekar S, Behera N, Daga SR,
Dutta AK, et al. A comparison of immunogenicity and safety of
indigenously developed liquid (DTwPHB-Hib) pentavalent combination
vaccine (Shan 5) with Easyfive (liq) and TritanrixHB + Hiberix (lyo) in
Indian infants administered according to the EPI schedule. Hum Vaccin.
2009;5:425-9.
36. Eregowda A, Lalwani S, Chatterjee S, Vakil H,
Ahmed K, Costantini M, et al. A phase III single arm,
multicenter, open-label study to assess the immunogenicity and
tolerability of a pentavalent DTwP-HepB-Hib vaccine in Indian infants.
Hum Vaccin Immunother. 2013;9:1903-9.
37. Phase III Clinical Trial Report of BBIL’s
pentavalent vaccine (DTwP-HepB-Hib) Comvac-5, Protocol No.BBIL/010/016.
38. Phase III Clinical Trial Report of Panacea
Biotech’s pentavalent vaccine (DTwP-HepB-Hib) Easyfive vaccine.
39. Package Insert (PI) of Easyfive-TT vaccine.
Available from:
http://www.who.int/immunization_standards/vaccine_quality/pq_269_dtp_hepb_hib_1dose_
panacea_ insert.pdf. Accessed July 7, 2014.
40. Package Insert (PI) of ComBEfive. Available from:
http://www.who.int/immunization_standards/vaccine_quality/pq_253_254_DTP_HepB_Hib_liquid_BiolE_PI.pdf.
Accessed July 7, 2014.
41. Asturias EJ, Contreras-Roldan IL, Ram M, Garcia-Melgar
AJ, Morales-Oquendo V, Hartman K, et al. Post-authorization
safety surveillance of a liquid pentavalent vaccine in Guatemalan
children. Vaccine. 2013;31:5909-14.
42. World Health Organization. WHO prequalified
vaccines. Available from: http://www.who.int/immunization_ standards/vaccine_quality/PQ_vaccine_list_en/en/.
Accessed July 12, 2014.
43. Schmid DA, Macura-Biegun A, Rauscher M.
Development and introduction of a ready-to-use pediatric pentavalent
vaccine to meet and sustain the needs of developing countries–Quinvaxem®:
the first 5 years. Vaccine. 2012;30:6241-48.
44. World Health Organization. A System for the
Prequalification of Vaccines for UN supply. Available from:
http://www.who.int/immunization_standards/vaccine_quality/pq_system/en/.
Accessed July 12, 2014.
|
|
|
|
|